Oncology

Yellowstone Biosciences launches to develop soluble bispecific cancer therapies

UK-based Yellowstone Biosciences has announced its launch with a £16.5m investment from Syncona to develop soluble bispecific T-cell receptor (TCR)-based therapies.

Iambic secures $50m to bolster clinical oncology programme pipeline

Clinical-stage biotechnology company Iambic Therapeutics has secured $50m in its Series B extension financing round to bolster its pipeline comprising artificial intelligence (AI)-discovered clinical oncology programmes.

Takeda, Ascentage Pharma sign option agreement for olverembatinib

Takeda has entered into an option agreement with Ascentage Pharma, securing the opportunity to obtain exclusive global licensing rights for olverembatinib, a third-generation BCR-ABL tyrosine kinase inhibitor (TKI).

Sibylla Biotech, MD Anderson to develop cancer treatments

Sibylla Biotech has entered into a strategic partnership with The University of Texas MD Anderson Cancer Center to advance the development of new cancer therapies.

Repare Therapeutics secures FDA Fast Track designation for ovarian cancer therapy

Repare Therapeutics has received Fast Track designation from the US Food and Drug Administration (FDA) for lunresertib in combination with camonsertib to treat adult patients with CCNE1 amplified, or FBXW7 or PPP2R1A-mutated platinum-resistant ovarian cancer.

ImmunoACT and Caring Cross sign TriCAR-T cell therapy development deal

India-based ImmunoAdoptive Cell Therapy (ImmunoACT) has entered into a partnership with Caring Cross to advance the development and commercialisation of a Tri-functional chimeric antigen receptor (TriCAR)-T cell immunotherapy aimed at treating leukaemia and lymphoma.

OverT Bio secures $16m in seed funding for cell therapy development

Data-driven biotechnology company OverT Bio has secured $16m in a seed funding round to expand its discovery platforms aimed at developing cellular therapies for solid tumours.

FDA accepts BLA for BMS’ subcutaneous nivolumab to treat solid tumours

The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) biologics license application (BLA) for the subcutaneous formulation of Opdivo (nivolumab) formulated along with Halozyme’s recombinant human hyaluronidase (rHuPH20) [referred as subcutaneous nivolumab] for previously approved solid tumour indications for the drug.

Celltrion secures new public tenders for two biosimilars in Peru

Biopharmaceutical company Celltrion has solidified its presence in the Latin American pharmaceutical market with a series of successful public tender wins in Peru.